Eton Pharmaceuticals Inc. (ETON) Misses Q3 EPS by 7c

Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q3 EPS of $0.04, $0.07 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $22.5 million versus the consensus estimate of $20.27 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Zenas BioPharma (ZBIO) files for up to 7M share offering by selling stockholders
• BetterLife Pharma files final prospectus for $100M public offering